AOD-9604 in Adiapoto-I — Fat Loss Peptide Research Guide
AOD-9604 research guide for Adiapoto-I. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 in Adiapoto-I — Research & Sourcing Guide
For anyone in Adiapoto-I searching for AOD-9604, the first thing to know is that this compound is distributed via specialist online vendors. The key implication for Adiapoto-I researchers: sourcing AOD-9604 hinges on vendor quality evaluation, not geography — and the framework for evaluating that quality is the same regardless of where you are. Vendors worth sourcing from openly share batch-matched Certificates of Analysis containing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. Use this guide to verify vendor quality systematically — the standards covered in this guide apply whether you are in Adiapoto-I or anywhere else.
AOD-9604: What the Research Shows
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Adiapoto-I studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy AOD-9604 — A Researcher's Guide
Before looking at individual vendors, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. A COA for AOD-9604 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. For Adiapoto-I researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is the accepted approach among experienced researchers. Keep lyophilised AOD-9604 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order AOD-9604 — ships to Adiapoto-I
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Endotoxin testing in the AOD-9604 COA is not optional — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no cost saving makes omitting this acceptable. Researchers using AOD-9604 alongside other research compounds should examine published studies for potential interaction data before beginning combination research.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
